Kodiak Sciences Inc
NASDAQ:KOD

Watchlist Manager
Kodiak Sciences Inc Logo
Kodiak Sciences Inc
NASDAQ:KOD
Watchlist
Price: 6.19 USD 4.92% Market Closed
Market Cap: 325.7m USD
Have any thoughts about
Kodiak Sciences Inc?
Write Note

Kodiak Sciences Inc
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kodiak Sciences Inc
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Kodiak Sciences Inc
NASDAQ:KOD
Tax Provision
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Tax Provision
-$2.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-6%
Gilead Sciences Inc
NASDAQ:GILD
Tax Provision
-$63m
CAGR 3-Years
68%
CAGR 5-Years
48%
CAGR 10-Years
30%
Amgen Inc
NASDAQ:AMGN
Tax Provision
-$449m
CAGR 3-Years
19%
CAGR 5-Years
19%
CAGR 10-Years
0%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Tax Provision
-$739.4m
CAGR 3-Years
-9%
CAGR 5-Years
-31%
CAGR 10-Years
-61%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Tax Provision
-$314.9m
CAGR 3-Years
33%
CAGR 5-Years
-20%
CAGR 10-Years
3%
No Stocks Found

Kodiak Sciences Inc
Glance View

Market Cap
325.7m USD
Industry
Biotechnology

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Palo Alto, California and currently employs 93 full-time employees. The company went IPO on 2018-10-04. The Company’s Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. The Company’s lead product candidate includes KSI-301, which is an antibody biopolymer conjugate being investigated in multiple pivotal studies in retinal vascular diseases, including wAMD, DME, RVO and non-proliferative diabetic retinopathy. KSI-301 is under Phase IIb/III clinical trials. The Company’s other pipeline candidates includes product candidates KSI-501 and KSI-601, which are developed for the treatment of other unmet needs in retina, such as dry AMD and glaucoma. The Company’s subsidiary includes Kodiak Sciences GmbH.

KOD Intrinsic Value
3.76 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

Back to Top